Abstract
The 5-HTR2A gene is a candidate gene for influencing the clinical response to antidepressant treatment. The purpose of this study was to determine the relationship between the -1438A/G polymorphism in the 5-HTR2A gene and the response to citalopram in a Korean population with major depressive disorder (MDD). Citalopram was administered for 4 weeks to the 71 patients who completed this study. We found significant differences in genotype, allele, and carrier distribution between the normal group and MDD patients (genotypes: χ2 = 6.473, d.f. = 2, p = 0.039; alleles: χ2 = 5.589, d.f. = 1, p = 0.018; OR = 0.618, 95% Cl = 0.414-0.922; allele carriers: χ2 = 5.383, d.f. = 1, p = 0.020; OR = 0.473, 95% Cl = 0.249-0.879). The frequency of the -1438G allele was much higher in MDD patients than in the normal group (allele carriers: χ2 = 5.383, d.f. = 1, p = 0.020; OR = 0.473, 95% Cl = 0.249-0.879). There were also significant differences in response to citalopram according to the -1438A/G variation of 5-HTR2A in MDD patients. The group of remitters carried a higher frequency of the GG allele than of the AA and AG alleles. More of nonremitters carried the A allele than were without it (genotype: χ2 = 8.016, p = 0.018; allele carrier: χ2 = 4.512, p = 0.034; OR = 0.324, 95% Cl = 0.112-0.936). The response to citalopram differed with the -1438A/G polymorphism genotype and allele carriers. The -1438G/-1438G genotype appeared to be associated with a better response to citalopram, with especially the G allele being related to core depressive symptoms and psychic anxiety improvement (p < 0.05). These results suggest that the G allele of the -1438A/G polymorphism in the 5-HTR2A gene is associated with MDD, and that patients with -1438G/-1438G have a better response to citalopram treatment than patients with -1438A/-1438A or -1438A/-1438G.
| Original language | English |
|---|---|
| Pages (from-to) | 155-162 |
| Number of pages | 8 |
| Journal | Neuropsychobiology |
| Volume | 52 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2005 Sep 1 |
Fingerprint
Keywords
- 5-HTR2A promoter polymorphism
- Antidepressant
- Citalopram
- Major depressive disorder
- Treatment response
ASJC Scopus subject areas
- Psychiatry and Mental health
- Neuroscience(all)
- Psychology(all)
Cite this
Serotonin receptor 2A gene polymorphism (-1438A/G) and short-term treatment response to citalopram. / Choi, Myoung J.; Kang, Rhee H.; Ham, Byung-Joo; Jeong, Han Yong; Lee, Min-Soo.
In: Neuropsychobiology, Vol. 52, No. 3, 01.09.2005, p. 155-162.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Serotonin receptor 2A gene polymorphism (-1438A/G) and short-term treatment response to citalopram
AU - Choi, Myoung J.
AU - Kang, Rhee H.
AU - Ham, Byung-Joo
AU - Jeong, Han Yong
AU - Lee, Min-Soo
PY - 2005/9/1
Y1 - 2005/9/1
N2 - The 5-HTR2A gene is a candidate gene for influencing the clinical response to antidepressant treatment. The purpose of this study was to determine the relationship between the -1438A/G polymorphism in the 5-HTR2A gene and the response to citalopram in a Korean population with major depressive disorder (MDD). Citalopram was administered for 4 weeks to the 71 patients who completed this study. We found significant differences in genotype, allele, and carrier distribution between the normal group and MDD patients (genotypes: χ2 = 6.473, d.f. = 2, p = 0.039; alleles: χ2 = 5.589, d.f. = 1, p = 0.018; OR = 0.618, 95% Cl = 0.414-0.922; allele carriers: χ2 = 5.383, d.f. = 1, p = 0.020; OR = 0.473, 95% Cl = 0.249-0.879). The frequency of the -1438G allele was much higher in MDD patients than in the normal group (allele carriers: χ2 = 5.383, d.f. = 1, p = 0.020; OR = 0.473, 95% Cl = 0.249-0.879). There were also significant differences in response to citalopram according to the -1438A/G variation of 5-HTR2A in MDD patients. The group of remitters carried a higher frequency of the GG allele than of the AA and AG alleles. More of nonremitters carried the A allele than were without it (genotype: χ2 = 8.016, p = 0.018; allele carrier: χ2 = 4.512, p = 0.034; OR = 0.324, 95% Cl = 0.112-0.936). The response to citalopram differed with the -1438A/G polymorphism genotype and allele carriers. The -1438G/-1438G genotype appeared to be associated with a better response to citalopram, with especially the G allele being related to core depressive symptoms and psychic anxiety improvement (p < 0.05). These results suggest that the G allele of the -1438A/G polymorphism in the 5-HTR2A gene is associated with MDD, and that patients with -1438G/-1438G have a better response to citalopram treatment than patients with -1438A/-1438A or -1438A/-1438G.
AB - The 5-HTR2A gene is a candidate gene for influencing the clinical response to antidepressant treatment. The purpose of this study was to determine the relationship between the -1438A/G polymorphism in the 5-HTR2A gene and the response to citalopram in a Korean population with major depressive disorder (MDD). Citalopram was administered for 4 weeks to the 71 patients who completed this study. We found significant differences in genotype, allele, and carrier distribution between the normal group and MDD patients (genotypes: χ2 = 6.473, d.f. = 2, p = 0.039; alleles: χ2 = 5.589, d.f. = 1, p = 0.018; OR = 0.618, 95% Cl = 0.414-0.922; allele carriers: χ2 = 5.383, d.f. = 1, p = 0.020; OR = 0.473, 95% Cl = 0.249-0.879). The frequency of the -1438G allele was much higher in MDD patients than in the normal group (allele carriers: χ2 = 5.383, d.f. = 1, p = 0.020; OR = 0.473, 95% Cl = 0.249-0.879). There were also significant differences in response to citalopram according to the -1438A/G variation of 5-HTR2A in MDD patients. The group of remitters carried a higher frequency of the GG allele than of the AA and AG alleles. More of nonremitters carried the A allele than were without it (genotype: χ2 = 8.016, p = 0.018; allele carrier: χ2 = 4.512, p = 0.034; OR = 0.324, 95% Cl = 0.112-0.936). The response to citalopram differed with the -1438A/G polymorphism genotype and allele carriers. The -1438G/-1438G genotype appeared to be associated with a better response to citalopram, with especially the G allele being related to core depressive symptoms and psychic anxiety improvement (p < 0.05). These results suggest that the G allele of the -1438A/G polymorphism in the 5-HTR2A gene is associated with MDD, and that patients with -1438G/-1438G have a better response to citalopram treatment than patients with -1438A/-1438A or -1438A/-1438G.
KW - 5-HTR2A promoter polymorphism
KW - Antidepressant
KW - Citalopram
KW - Major depressive disorder
KW - Treatment response
UR - http://www.scopus.com/inward/record.url?scp=24944471356&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=24944471356&partnerID=8YFLogxK
U2 - 10.1159/000087847
DO - 10.1159/000087847
M3 - Article
C2 - 16127283
AN - SCOPUS:24944471356
VL - 52
SP - 155
EP - 162
JO - Neuropsychobiology
JF - Neuropsychobiology
SN - 0302-282X
IS - 3
ER -